Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

PDF-Funded Research Paves the Way to Phase III Drug Trial

The Parkinson’s Disease Foundation (PDF) is pleased to announce that research initially launched with PDF funding will be tested in a phase III clinical trial A research study in humans that aims to test a new intervention – this could be a drug, surgery or therapy like exercise or diet guidelines – to make sure it is effective and safe. opening in 2016. The study, which two of PDF’s volunteer Research Advocates are helping to oversee, is assessing the potential of the nutritional supplement inosine for the treatment of Parkinson’s disease.

Several studies, including early research funded by PDF in 2007 through its grant to the Parkinson Study Group, have shown that high levels of urate (a naturally occurring salt in the body) are associated with slower rate of progression in Parkinson’s disease. The PDF-funded retrospective study entitled, "Predicting PD Progression Subtypes by CSF Urate Pathways,” led by Michael Schwarzschild, M.D., Ph.D., of MassGeneral Institute of Neurodegenerative Disease, looked at urate levels in thousands of people with PD who had participated in clinical trials.

This early research paved the way for Dr. Schwarzschild to study a nutritional supplement called inosine, which the body converts to urate, for its potential as a treatment for Parkinson’s disease. This research has now progressed to a phase III clinical trial called SURE-PD3 (Study of URate Elevation in Parkinson’s Disease) — the final stage of research before a new treatment can be approved by the US Food and Drug Administration (FDA) for use by the public.

PDF is pleased that two of its Research Advocates have active roles on the clinical trial — representing the Parkinson’s community and ensuring that the patient perspective is central.

Becky Houde, J.D. of Boston, MA: is a member of the SURE-PD3 steering committee, the group that oversees and supervises the trial.

Joel Grace, Ph.D., of Big Flats, NY: is a member of the SURE-PD3 Data Safety and Monitoring Board, the group that monitors the safety of all trial participants.

Enrollment for the double-blinded placebo-controlled trial will begin in 2016, and will seek 270 people living with early-stage Parkinson’s to investigate whether moderate urate elevation resulting from two years of inosine treatment slows PD progression. It will be conducted at 60 Parkinson Study Group sites across the US and is supported by the National Institute of Neurological Disorders and Stroke.

Wednesday, September 2, 2015
Parkinson’s Foundation Awards New Nurse Faculty Grant to Four Nurses Specializing in Parkinson’s Care
Thursday, October 11, 2018

NEW YORK & MIAMI — October 11, 2018 — The Parkinson’s Foundation announced that it has awarded its first-ever Parkinson’s Foundation Nurse Faculty Award to four nurses, totaling $30,000. The nurses, all graduates of the Edmond J.

Update on NUPLAZID — FDA finds no new or unexpected safety risks
Friday, September 21, 2018

On September 20, 2018, the U.S.

Parkinson’s Foundation Extends Bilingual National Helpline Hours
Tuesday, September 18, 2018

NEW YORK & MIAMI — September 18, 2018 — The Parkinson’s Foundation announced today that its toll-free Helpline, 1-800-4PD-INFO, will extend its hours, answering calls in English and Spanish, to help make life better for people with Parkinson’s disease (PD) and their families.

Parkinson’s Foundation Hosts Allied Team Training for Parkinson’s in Atlanta
Tuesday, September 11, 2018

NEW YORK & MIAMI—September 11, 2018—The Parkinson’s Foundation today announced the location of its signature professional education program course, Allied Team Training for Parkinson’s, ATTP®, for health care professionals treating patients with Parkinson’s disease, in Atlanta.

Parkinson’s Foundation Increases Funding to $6.2 Million to Advance Parkinson’s Research
Tuesday, August 14, 2018

NEW YORK & MIAMI — August 14, 2018 — The Parkinson’s Foundation announced today an increased investment of $6.2 million across 53 research grants to support the work of promising scientists in the field of Parkinson's disease (PD) in 2018.

PD Gladiators Merges with the Parkinson’s Foundation Expanding Reach in Greater Atlanta Parkinson’s Community
Wednesday, August 1, 2018

ATLANTA – August 1, 2018—PD Gladiators, Inc., an Atlanta-based nonprofit organization focused on combatting Parkinson’s disease (PD) with vigorous exercise, has merged with the Parkinson’s Foundation (PF), a non-profit organization whose mission is to make life better for people with PD worldwide through expert care and research.

Parkinson’s Foundation Partners with Medscape Education to Deliver Patient Education
Monday, July 30, 2018

July 30, 2018—The Parkinson’s Foundation has collaborated with Medscape Education to launch an online learning program entitled “Parkinson’s Disease Psychosis: A Learning Destination for Care Partners and Patients,” available on Medscape’s patient portal, WebMD Education.

Parkinson’s Foundation Designates Three Centers of Excellence in Parkinson’s Care: Global Network Expands to 45 Parkinson’s Centers
Tuesday, July 24, 2018

MIAMI & NEW YORK CITY — July 24, 2018 — The Parkinson’s Foundation today announced the addition of three new Centers of Excellence to its global network: Cleveland Clinic; Medical University of South Carolina; and University of Iowa Hospitals and Clinics.

Parkinson’s Foundation Funds $450,000 for Local Parkinson’s Programs in Seven Cities Across the Country
Monday, July 23, 2018

NEW YORK & MIAMI — July 23, 2018 — The Parkinson's Foundation today announced it will fund nearly $450,000 to local community grants in seven cities that hosted the Foundation's annual fundraiser, Moving Day, A Walk for Parkinson's, in 2017. These grants will further the health, wellness and education of people with Parkinson's disease (PD).

In Memory of Robert Traurig
Wednesday, July 18, 2018

The Parkinson’s Foundation mourns the loss of emeritus board member Robert (Bob) Traurig. From 2004 to 2015, he was a member of the Foundation’s board of directors. Bob is survived by his wife Jacqueline, his daughters Madeline Sackel and Wendy Traurig.

Pages

mail icon

Subscribe here to get the latest news on treatments, research and other updates.